These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 19152640)
1. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it. Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640 [TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors. Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425 [TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors. Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317 [TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors. Deng XQ; Wang HY; Zhao YL; Xiang ML; Jiang PD; Cao ZX; Zheng YZ; Luo SD; Yu LT; Wei YQ; Yang SY Chem Biol Drug Des; 2008 Jun; 71(6):533-9. PubMed ID: 18410307 [TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors. Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613 [TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Xie HZ; Li LL; Ren JX; Zou J; Yang L; Wei YQ; Yang SY Bioorg Med Chem Lett; 2009 Apr; 19(7):1944-9. PubMed ID: 19254842 [TBL] [Abstract][Full Text] [Related]
7. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418 [TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543 [TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors. Chen JJ; Liu TL; Yang LJ; Li LL; Wei YQ; Yang SY Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):704-9. PubMed ID: 19571415 [TBL] [Abstract][Full Text] [Related]
10. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors. Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012 [TBL] [Abstract][Full Text] [Related]
11. Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors. Xie HZ; Liu LY; Ren JX; Zhou JP; Zheng RL; Li LL; Yang SY J Biomol Struct Dyn; 2011 Aug; 29(1):165-79. PubMed ID: 21696232 [TBL] [Abstract][Full Text] [Related]
12. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies. Yu H; Wang Z; Zhang L; Zhang J; Huang Q Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906 [TBL] [Abstract][Full Text] [Related]
13. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors. Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393 [TBL] [Abstract][Full Text] [Related]
14. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors. Saxena S; Chaudhaery SS; Varshney K; Saxena AK SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581 [TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. Yu H; Wang Z; Zhang L; Zhang J; Huang Q Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530 [TBL] [Abstract][Full Text] [Related]
16. A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors. Adane L; Bharatam PV; Sharma V J Enzyme Inhib Med Chem; 2010 Oct; 25(5):635-45. PubMed ID: 19995305 [TBL] [Abstract][Full Text] [Related]
17. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies. Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816 [TBL] [Abstract][Full Text] [Related]
18. Computational approach to the identification of novel Aurora-A inhibitors. Morshed MN; Cho YS; Seo SH; Han KC; Yang EG; Pae AN Bioorg Med Chem; 2011 Jan; 19(2):907-16. PubMed ID: 21194953 [TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors. Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015 [TBL] [Abstract][Full Text] [Related]
20. Ligand-based virtual screening and molecular docking studies to identify the critical chemical features of potent cathepsin D inhibitors. Sakkiah S; Thangapandian S; Lee KW Chem Biol Drug Des; 2012 Jul; 80(1):64-79. PubMed ID: 22269155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]